These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Afatinib: a second-generation EGF receptor and ErbB tyrosine kinase inhibitor for the treatment of advanced non-small-cell lung cancer. Marquez-Medina D; Popat S Future Oncol; 2015 Sep; 11(18):2525-40. PubMed ID: 26314834 [TBL] [Abstract][Full Text] [Related]
6. Next-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on Afatinib. Hirsh V BioDrugs; 2015 Jun; 29(3):167-83. PubMed ID: 26123538 [TBL] [Abstract][Full Text] [Related]
7. [EGFR inhibitors in non-small cell lung cancer: more than yesterday (but less than tomorrow)]. Cortot AB Rev Pneumol Clin; 2010 Dec; 66(6):367-74. PubMed ID: 21167447 [TBL] [Abstract][Full Text] [Related]
8. Epidermal growth factor receptor inhibition and non-small cell lung cancer. von Eyben FE Crit Rev Clin Lab Sci; 2006; 43(4):291-323. PubMed ID: 16769595 [TBL] [Abstract][Full Text] [Related]
10. [Mechanism of action and preclinical development of afatinib]. Diz Taín P; González AL; García-Palomo A Med Clin (Barc); 2016 Apr; 146 Suppl 1():7-11. PubMed ID: 27426242 [TBL] [Abstract][Full Text] [Related]
11. Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors. Blackledge G; Averbuch S Br J Cancer; 2004 Feb; 90(3):566-72. PubMed ID: 14760365 [TBL] [Abstract][Full Text] [Related]
12. Clinical Utility of Patient-Derived Xenografts to Determine Biomarkers of Prognosis and Map Resistance Pathways in EGFR-Mutant Lung Adenocarcinoma. Stewart EL; Mascaux C; Pham NA; Sakashita S; Sykes J; Kim L; Yanagawa N; Allo G; Ishizawa K; Wang D; Zhu CQ; Li M; Ng C; Liu N; Pintilie M; Martin P; John T; Jurisica I; Leighl NB; Neel BG; Waddell TK; Shepherd FA; Liu G; Tsao MS J Clin Oncol; 2015 Aug; 33(22):2472-80. PubMed ID: 26124487 [TBL] [Abstract][Full Text] [Related]
13. Medical treatment of non-small-cell lung cancer. Buter J; Giaccone G Ann Oncol; 2005; 16 Suppl 2():ii229-32. PubMed ID: 15958463 [No Abstract] [Full Text] [Related]
14. Use of cetuximab after failure of gefitinib in patients with advanced non-small-cell lung cancer. Wu JY; Yang CH; Hsu YC; Yu CJ; Chang SH; Shih JY; Yang PC Clin Lung Cancer; 2010 Jul; 11(4):257-63. PubMed ID: 20630828 [TBL] [Abstract][Full Text] [Related]
16. Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers. Yonesaka K; Zejnullahu K; Lindeman N; Homes AJ; Jackman DM; Zhao F; Rogers AM; Johnson BE; Jänne PA Clin Cancer Res; 2008 Nov; 14(21):6963-73. PubMed ID: 18980991 [TBL] [Abstract][Full Text] [Related]
17. EGFR pathway in advanced non-small cell lung cancer. Merlo V; Longo M; Novello S; Scagliotti GV Front Biosci (Schol Ed); 2011 Jan; 3(2):501-17. PubMed ID: 21196393 [TBL] [Abstract][Full Text] [Related]
18. [Molecular diagnostics in lung carcinoma for therapy stratification]. Heukamp LC; Büttner R Pathologe; 2010 Feb; 31(1):22-8. PubMed ID: 19997736 [TBL] [Abstract][Full Text] [Related]
19. Comparing the effects of afatinib with gefitinib or Erlotinib in patients with advanced-stage lung adenocarcinoma harboring non-classical epidermal growth factor receptor mutations. Shen YC; Tseng GC; Tu CY; Chen WC; Liao WC; Chen WC; Li CH; Chen HJ; Hsia TC Lung Cancer; 2017 Aug; 110():56-62. PubMed ID: 28676220 [TBL] [Abstract][Full Text] [Related]
20. Afatinib in the treatment of EGFR mutation-positive NSCLC--a network meta-analysis. Popat S; Mok T; Yang JC; Wu YL; Lungershausen J; Stammberger U; Griebsch I; Fonseca T; Paz-Ares L Lung Cancer; 2014 Aug; 85(2):230-8. PubMed ID: 24929780 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]